Anti-TNF agentsYear: 2017
Source: 15th IBD Intensive Advanced Course
Authors: Baert F.
Last Modified: Monday, 10 May 2021, 11:49 AM by ECCO Administrator
Anti TNF drug levels, Anti drug antibodies, Therapeutic drug monitoring, Anti-TNF agents
Files: 1
Crohn's disease: Perianal disease e-CourseYear: 2020
Source: e-Course
Authors: Federica Furfaro, Kostas Katsanos, Pascal Juillerat, Pierre Ellul
Created: Friday, 28 February 2020, 11:37 AM by Dauren Ramankulov
Last Modified: Wednesday, 2 June 2021, 2:00 PM by ECCO Administrator
This course has been developed by physicians who had recently participated in the writing of the ECCO Crohn's disease consensus Guidelines. This course is intended for those who are interested in Inflammatory Bowel Disease(s) (IBD). One major aim of this e-learning activity is to increase competence and knowledge with regard to Perianal disease in order to improve patient outcomes.
After this case you will:
- To appreciate the Crohn’s disease natural history
- To appreciate the rationale behind specific treatment decisions
- To understand the right investigations to prescribe to Crohn’s disease patient in specific settings
- To learn appropriate clinical management of Crohn’s disease patients with perianal involvement
Luminal Crohn's disease e-CourseYear: 2020
Source: e-Course
Authors: João Sabino, Bram Verstockt, Kostas Katsanos, Pascal Juillerat, Pierre Ellul
Created: Friday, 28 February 2020, 11:33 AM by Dauren Ramankulov
Last Modified: Wednesday, 2 June 2021, 1:58 PM by ECCO Administrator
This course has been developed by physicians who had recently participated in the writing of the ECCO Crohn's disease consensus Guidelines. This course is intended for those who are interested in Inflammatory Bowel Disease(s) (IBD). One major aim of this e-learning activity is to increase competence and knowledge with regard to Luminal disease in order to improve patient outcomes.
Upon completion of this case you will:
- Know the evidence for induction of remission in mild-to-moderate Crohn’s disease;
- Know the evidence for maintaining remission in Crohn’s disease;
- Know the evidence on how to react upon disease flares, immediately after induction therapy or during maintenance therapy;
- Understand the benefits and risks of several medical therapies;
- Achieve familiarity how to use immunomodulatory agents in mono- or combination therapy;
- Achieve familiarity how to monitor Crohn’s disease patients who initiated medical therapy or who underwent surgery;
- Recognise indications for surgical management.
UC ManagementYear: 2020
Source: 11th N-ECCO School
Authors: Mark Samaan
Created: Tuesday, 23 June 2020, 4:58 PM
Last Modified: Thursday, 17 June 2021, 4:02 PM by ECCO Administrator
Files: 1
UC ManagementYear: 2020
Source: 11th N-ECCO School
Authors: Mark Samaan
Created: Tuesday, 23 June 2020, 5:40 PM
Last Modified: Thursday, 17 June 2021, 4:02 PM by ECCO Administrator
UstekinumabYear: 2017
Source: 15th IBD Intensive Advanced Course
Authors: Ferrante M.
Last Modified: Monday, 10 May 2021, 12:01 PM by ECCO Administrator
Crohn's disease, Disease activity Indices, Ustekinumab, Colonoscopy
Files: 1
VedolizumabYear: 2017
Source: 15th IBD Intensive Advanced Course
Authors: Lindsay J.
Last Modified: Monday, 10 May 2021, 11:50 AM by ECCO Administrator
Therapeutic drug monitoring, Vedolizumab
Files: 1
VedolizumabYear: 2019
Source: Educational Audio Podcasts
Authors: Uri Kopylov
Created: Friday, 28 February 2020, 4:03 PM by Dauren Ramankulov
Last Modified: Wednesday, 2 June 2021, 5:19 PM by ECCO Administrator